Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 22 years of age~* Have undergone a brain biopsy via stereotactic or open technique~* Pathological evidence of GBM using WHO classification criteria~* Planned 6 weeks of concurrent chemoradiotherapy post-biopsy concomitant with temozolomide (45-70Gy)~* Karnofsky scale greater than or equal to 70~* Life expectancy at least 3 months~* Baseline hemoglobin of \> 8.0 gm/dL (with or without transfusion)~* Adequate coagulation defined as PT and INR \< 1.5 times the upper limit of normal~* Signed informed consent~* Able to start bevacizumab at least 2 weeks but no more than 4 weeks from date of biopsy~* Able to tolerate MRI of brain and have measurable disease.~* Participants of childbearing age must use effective contraception for at least 6 months following completion of treatment.~Exclusion Criteria~* Enrolled in another clinical treatment trial~* Pregnant or Breast-feeding~* Any other malignancy aside from localized basal cell or squamous cell carcinoma of the skin~* Significant co-morbidities at baseline which would prevent maintenance temozolomide~* Thrombocytopenia (platelet count \< 100 x 103 )~* Neutropenia (absolute neutrophil count \< 1.5 x 103 )~* CTC grade 4 non-hematological toxicity (except for alopecia, nausea, vomiting)~* Significant liver function impairment - AST or ALT \> 3 times the upper limit of normal~* Total bilirubin\> 2 times the upper limit of normal~* Significant renal impairment (serum creatinine\> 1.7 mg/dL)~* Implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, other implanted electronic devices in the brain, or documented clinically significant arrhythmias.~* Infra-tentorial tumor~* Evidence of increased intracranial pressure (midline shift \> 5mm, clinically significant papilledema, vomiting and nausea, or reduced level of consciousness)~* History of hypersensitivity reaction to temozolomide or a history of hypersensitivity to DTIC or hydrogel~* Inability to adequately cover treatment area with TTFields (Tumor Treating Fields)~* Inability to wear NovoTTF-100A System for an average of 18 hours per 24 hours~* Currently taking cytotoxic medications, non-steroidal ant-inflammatory drugs (NSAIDS), or enzyme inducing anticonvulsants.~* Currently taking anticoagulants or blood-thinners (Coumadin)~* Subjects meeting any of the following bevacizumab-specific contraindications are ineligible for study entry:~* Inadequately controlled hypertension (defined as systolic blood pressure greater than or equal to 150 and/or diastolic blood pressure \> 100 mmHg)~* Prior history of hypertensive crisis or hypertensive encephalopathy~* New York Heart Association (NYHA) Grade II or greater congestive heart failure~* History of myocardial infarction or unstable angina within 6 months prior to study enrollment~* History of stroke or transient ischemic attack within 6 months prior to study enrollment~* Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to study enrollment~* History of hemoptysis (greater than or equal to a half teaspoon of bright red blood per episode) within 1 month prior to study enrollment~* Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation)~* Major surgical procedure or significant traumatic injury within 28 days prior to 1st bevacizumab infusion or anticipation of need for major surgical procedure during the course of the study~* Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment~* History of abdominal fistula, gastrointestinal perforation within 6 months prior to study enrollment~* Serious, non-healing wound, active ulcer, or untreated bone fracture~* Proteinuria at screening as demonstrated by either urine protein: creatinine (UPC) ratio greater than or equal to 1.0 at screening OR urine dipstick for proteinuria greater than or equal to 2 or more (patients discovered to have greater than or equal to 2 or greater proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate less than or equal to 1g of protein in 24 hours to be eligible).~* Known hypersensitivity to any component of bevacizumab

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Planned RT + TMZ + BEV + NovoTTF100A Device (Type: EXPERIMENTAL): Best standard of care radiation therapy (RT, 2 Gy given daily 5 days per week), temozolomide (TMZ, 75 mg/m2 administered daily), and bevacizumab (BEV, 10 mg/kg administered every 2 weeks as an IV infusion) for 6 weeks. After completion of chemoradiation, NovoTTF100A system was initiated, to be worn on average 18 hours or more a day for up to 12 months. The patients also continued with maintenance TMZ/BEV.

Based on this trial design, predict the completion outcome and termination type (if applicable).